A group of oral anti-diabetic drugs designed to treat patients with type 2 diabetes. Thiazolidenediones are compounds that act as agonists of the peroxisome proliferator-activated receptor-gamma increasing tissues sensibility (muscle, adiposity tissue, and liver) to insulin action.
|Drug||Drug Name||Drug Indication|
|DB00412||Rosiglitazone||Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|
|DB01132||Pioglitazone||Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [FDA Label].|
|DB09198||Lobeglitazone||Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.|
|DB00197||Troglitazone||For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.|